Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Debt to Equity (2017 - 2026)

Aytu Biopharma has reported Debt to Equity over the past 14 years, most recently at $0.83 for Q4 2025.

  • Quarterly Debt to Equity rose 83.51% to $0.83 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.83 through Dec 2025, up 83.51% year-over-year, with the annual reading at $1.05 for FY2025, 129.04% up from the prior year.
  • Debt to Equity was $0.83 for Q4 2025 at Aytu Biopharma, down from $1.09 in the prior quarter.
  • Over five years, Debt to Equity peaked at $1.09 in Q3 2025 and troughed at $0.01 in Q4 2021.
  • The 5-year median for Debt to Equity is $0.41 (2022), against an average of $0.43.
  • Year-over-year, Debt to Equity crashed 88.0% in 2021 and then surged 2423.07% in 2022.
  • A 5-year view of Debt to Equity shows it stood at $0.01 in 2021, then surged by 2423.07% to $0.32 in 2022, then skyrocketed by 52.63% to $0.49 in 2023, then dropped by 6.62% to $0.45 in 2024, then surged by 83.51% to $0.83 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Debt to Equity are $0.83 (Q4 2025), $1.09 (Q3 2025), and $1.05 (Q2 2025).